793-10-2

Upstream product

• 770-12-7 O-phenyl phosphorodichloridate 
• 824-78-2 4-nitrophenol sodium salt 
• 100-02-7 4-nitro-phenol 
• 777-52-6 1-dichlorophosphoryloxy-4-nitro-benzene 
• 108-95-2 phenol 

Downstream Products

• 1776-93-8 ethyl phenyl (4-nitrophenyl)phosphonate 
• 94189-85-2 Phosphoric acid (2R,3S,5R)-5-(6-amino-purin-9-yl)-3-(tert-butyl-dimethyl-silanyloxy)-tetrahydro-furan-2-ylmethyl ester 4-nitro-phenyl ester phenyl ester 
• 84915-31-1 Phosphoric acid (2R,3S,5R)-5-(6-amino-purin-9-yl)-2-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-3-yl ester 4-nitro-phenyl ester phenyl ester 
• 1190308-01-0 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy](phenoxy)phosphorylamino}propionic acid isopropyl ester 
• 1190307-88-0 sofosbuvir 
• 1334513-09-5 (S)-isopropyl 2-(((S)-(((3aR,4R,6R,6aR)-6-(6-amino-0H-purin-9-yl)-2,2-dimethyltetrahydrofuro-[3,4-d]dioxol-4-yl)methoxy)(phenoxy)phosphoryl)amino)propionoate 
• 1256490-31-9 (S)-2-[(S)-(4-nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid isopropyl ester 
• 1256490-49-9 (S)-2-[(R)-(4-nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid isopropyl ester 
• 1256490-48-8 (S)-2-[(4-nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid isopropyl ester 
• 84915-33-3 phenyl 5'-O-t-butyldimethylsilyl-2'-deoxyadenylyl(3'-5')-3'-O-t-butyldimethylsilyl-2'-deoxyadenosine 
• 94189-92-1 phenyl 5'-O-t-butyldimethylsilyl-2'-deoxycytidylyl(3'-5')-3'-O-t-butyldimethylsilyl-2'-deoxyadenosine 
• 793-11-3 Phenyl-<4-nitro-phenyl>-phosphamid 
• 793-12-4 phenyl(p-nitrophenyl)phosphoric acid 
• 94189-95-4 C₆₈H₇₃Cl₂N₁₅O₁₄P₂Si 

Relevant academic research and scientific papers

NUCLEOTIDE PRODRUGS

The invention relates to nucleotide prodrugs and pharmaceutical preparations thereof. The invention further relates using the prodrugs of the invention in the treatment of mitochondrial DNA (mtDNA) depletion syndrome (MDS).

NUCLEIC ACID PRODRUGS

The invention relates to nucleotide prodrugs and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel prodrugs of the invention.

(S)- 2 - [(s)- (4 - nitro - phenoxy) - phenoxy - phosphoryl amino] isopropyl propionate preparation method

The invention relates to a preparation method of (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate. The (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate, which is excellent in chemical purity and optical purity, is prepared by the following steps: preparing a compound as shown in a formula (III) from phenoxy dichlorophosphite as shown in a formula (I) and nitrophenol as shown in a formula (II), preparing a compound as shown in formula (V) from the compound as shown in the formula (III) and L-alanine isopropyl ester hydrochloride, and implementing solvent recrystallization on the compound as shown in the formula (V). The preparation method disclosed by the invention has the beneficial effects that the method for preparing the (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate is simple in technological process and convenient to operate, and meanwhile the method is high in both purity and yield and is applicable to mass production.

DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES

The invention relates to a new synthethic process for obtaining compounds of formula (I) from compounds of formula (II) by means of cytidine deaminase enzymes.

Synthesis of diastereomerically pure nucleotide phosphoramidates

Prodrugs of therapeutic nucleoside monophosphates masked as phosphoramidate derivatives have become an increasingly important class of antiviral drugs in pharmaceutical research for delivering nucleotides in vitro and in vivo. Conventionally, phosphoramidate derivatives are prepared as a mixture of two diastereomers. We report a class of stable phosphoramidating reagents containing an amino acid ester and two phenolic groups, one unsubstituted and the other with electron-withdrawing substituents. The reagents can be isolated as single diastereomers and reacted with the 5′-hydroxyl group of nucleosides through selective nucleophilic displacement of the substituted phenol to prepare single diastereomer phosphoramidate products. This method has been used to prepare the HCV clinical candidate PSI-7977 in high yield and high diastereomeric purity.